70 related articles for article (PubMed ID: 7867384)
1. A new experimental and clinical approach of combining usage of highly active tumor-infiltrating lymphocytes and highly sensitive antitumor drugs for the advanced malignant tumor.
Li BR; Tong SQ; Zhang XH; Lu J; Gu QL; Lu DY
Chin Med J (Engl); 1994 Nov; 107(11):803-7. PubMed ID: 7867384
[TBL] [Abstract][Full Text] [Related]
2. Tumor tissue recycling--a new combination treatment for solid tumors: experimental and preliminary clinical research.
Li B; Ding J; Larson A; Song S
In Vivo; 1999; 13(5):433-8. PubMed ID: 10654199
[TBL] [Abstract][Full Text] [Related]
3. [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma].
Zhang YX; Wang XY; Liu JB; Zhang SQ; Chen YR
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):973-6. PubMed ID: 18756970
[TBL] [Abstract][Full Text] [Related]
4. Enhanced cytolytic activity of tumor infiltrating lymphocytes (TILs) derived from an ICAM-1 transfected tumor in a murine model.
Lefor AT; Fabian DF
J Surg Res; 1998 Feb; 75(1):49-53. PubMed ID: 9614856
[TBL] [Abstract][Full Text] [Related]
5. [A clinical study on adoptive immunotherapy of bone metastatic neoplasm with tumor infiltrating lymphocytes].
Hua JM; Zheng ZG; Xu GD
Zhonghua Zhong Liu Za Zhi; 1994 May; 16(3):203-6. PubMed ID: 7956700
[TBL] [Abstract][Full Text] [Related]
6. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL
Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513
[TBL] [Abstract][Full Text] [Related]
7. [Tumor infiltrating lymphocytes inhibit spontaneous lung metastasis of LA795 adenocarcinoma in mice].
Shen YQ; Lai BT; Wang H
Zhonghua Jie He He Hu Xi Za Zhi; 1994 Jun; 17(3):165-7, 191. PubMed ID: 7834774
[TBL] [Abstract][Full Text] [Related]
8. Postoperative immunotherapy for patients with hepatocarcinoma using tumor-infiltrating lymphocytes.
Wang Y; Chen H; Wu M; Bao J; Cong W; Wang H
Chin Med J (Engl); 1997 Feb; 110(2):114-7. PubMed ID: 9594281
[TBL] [Abstract][Full Text] [Related]
9. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes.
Weidmann E; Logan TF; Yasumura S; Kirkwood JM; Trucco M; Whiteside TL
Cancer Res; 1993 Oct; 53(20):4745-9. PubMed ID: 8402652
[TBL] [Abstract][Full Text] [Related]
10. [The role of CDDP on cytotoxicity of TILs obtained from colorectal tumors].
Xu Z; Qi X; Liu F
Zhonghua Wai Ke Za Zhi; 1997 May; 35(5):265-7. PubMed ID: 10374556
[TBL] [Abstract][Full Text] [Related]
11. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
[TBL] [Abstract][Full Text] [Related]
12. Characterization of IL-2-activated TILs and their use in intrapericardial immunotherapy in malignant pericardial effusion.
Toh U; Fujii T; Seki N; Niiya F; Shirouzu K; Yamana H
Cancer Immunol Immunother; 2006 Oct; 55(10):1219-27. PubMed ID: 16362409
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
14. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
15. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells.
Guo YS; Xing ZL
Chin Med J (Engl); 1994 Dec; 107(12):903-5. PubMed ID: 7882727
[TBL] [Abstract][Full Text] [Related]
16. Immunologic features of tumor-infiltrating lymphocytes and peripheral blood lymphocytes in ovarian cancer patients.
Schöndorf T; Engel H; Kurbacher CM; Brenne U; Kolhagen H; Göhring UJ; Scharl A; Mallmann P
J Soc Gynecol Investig; 1998; 5(2):102-7. PubMed ID: 9509389
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
[TBL] [Abstract][Full Text] [Related]
18. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
19. [Study on the influence of enzymatic digestion upon tumor-infiltrating lymphocytes].
Li BR; Tong SQ; Hu BY; Zhu YM; Zhang XH; Wu JH; Lu J; Lu DY
Shi Yan Sheng Wu Xue Bao; 1994 Mar; 27(1):103-7. PubMed ID: 8042406
[TBL] [Abstract][Full Text] [Related]
20. [The relationship between TIL from human primary hepatic carcinoma and prognosis].
Qin J; Han B; Pang J
Zhonghua Yi Xue Za Zhi; 1997 Mar; 77(3):167-70. PubMed ID: 9596951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]